Celmed BioSciences to present at the Rodman & Renshaw Techvest Healthcare Conference in New York.MONTREAL -- Celmed BioSciences announces that Mr. Jacques Deforges, Vice President Finance and Chief Financial Officer of the Company, will be presenting tomorrow, Tuesday, October 26, 2004 at 4:15 p.m. at the Rodman and Renshaw Techvest 6th annual Healthcare Conference. The conference is taking place at the Waldorf-Astoria Hotel in New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of from October 26 to 28. Webcast A live webcast of the presentation will be available on the event website at the following address: http://www.wallstreetwebcasting.com/webcast/rrshq4/celmed and will be archived for 90 days. About Celmed BioSciences Celmed BioSciences Inc. is a private Canadian biopharmaceutical company developing breakthrough products to treat cancer. The Company applies rational drug design and pharmacogenomic concepts to improve cancer patient care, an approach that offers significant potential both in terms of efficacy and safety to the patient. Celmed's two lead products, Theralux(TM) and NB1011, are currently in Phase I/II clinical development. Theralux(TM), a photodynamic-based therapy, is being evaluated in three therapeutic areas: the prevention of graft-versus-host disease graft-versus-host disease n. A type of incompatibility reaction of transplanted cells against host tissues that possess an antigen not possessed by the donor. Also called graft-versus-host reaction. (GvHD), the treatment of autoimmune diseases Autoimmune diseases A group of diseases, like rheumatoid arthritis and systemic lupus erythematosus, in which immune cells turn on the body, attacking various tissues and organs. Mentioned in: Complement Deficiencies, Premature Menopause by extracorporal photochemotherapy (ECP (Enhanced Capabilities Port) See IEEE 1284. 1. ECP - Engineering Change Proposal. 2. ECP - Enhanced Capabilities Port. 3. ECP - Extended Capabilities Port. 4. ECP - Extended Concurrent Prolog. ) and the purge of cancerous cells from bone marrow transplants bone marrow transplant: see bone marrow. in non-Hodgkin's lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma (NHL NHL Non-Hodgkin's lymphoma, see there ). NB1011, a Trojan horse solution to treating cancer, exploits the over-expression of the thymidylate synthase (TS) enzyme to destroy cancer cells. Celmed is currently planning a second Phase I/II study in various types of solid tumor cancers exhibiting high levels of TS, such as colorectal, lung, ovarian and breast cancer. More information about Celmed can be found at www.celmedbio.com. This press release contains forward-looking statements, which reflect Celmed's current expectations regarding future development of its products and technologies. Such statements inherently involve numerous risks and uncertainties, including the availability of funds and resources to pursue preclinical and clinical projects, the successful and timely completion of clinical studies, and the granting of the necessary authorizations by the regulatory authorities. Actual future results may differ materially from the anticipated results expressed in the forward-looking statements contained in this press release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion